Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03367871
Title Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors University of Miami

cervical squamous cell carcinoma

cervical adenosquamous carcinoma

cervical adenocarcinoma


Cisplatin + Paclitaxel + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.